6 completed, 2 recruiting, 2 terminated, 2 withdrawn. 8 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 3, Terminated 2, Withdrawn 2, Recruiting 1 |
| Phase 1 | 7 | Completed 6, Recruiting 1 |
Follow MedPacto, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment Patterns and Survival Outcomes in High-Grade Osteosarcoma: A Multicenter Retrospective Study High-Grade Osteosarcoma | Recruiting | MedPacto, Inc. | 400 | 2026-07-13 | 2026-10-16 | |
| Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma Vactosertib - Osteosarcoma | Phase 1 / Phase 2 | Recruiting | MedPacto, Inc. | 78 | 2023-05-01 | 2026-10-07 |
| Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF) Vactosertib, Imatinib - Dermoid | Phase 2 | Withdrawn | MedPacto, Inc. | 2021-06-01 | 2024-12-09 | |
| Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects Vactosertib 300 mg BID and pembrolizumab 200 mg IV - Carcinoma, Non-Small-Cell Lung | Phase 2 | Terminated | MedPacto, Inc. | 11 | 2020-12-17 | 2024-12-09 |
| Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition Vactosertib(TEW-7197)/ Durvalumab - Urothelial Carcinoma Recurrent, Advanced Urothelial Carcinoma | Phase 2 | Withdrawn | MedPacto, Inc. | 2019-12-13 | 2024-12-09 | |
| Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases Hepatectomy, Pembrolizumab, Vactosertib - Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8 | Phase 2 | Terminated | Chloe Atreya, MD, PhD | 6 | 2019-07-22 | 2025-12-31 |
| Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC TEW-7197 - Non-Small Cell Lung Cancer Metastatic | Phase 1 / Phase 2 | Completed | MedPacto, Inc. | 60 | 2019-02-11 | 2025-04-10 |
| Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer TEW-7197 - Metastatic Colorectal Cancer, Gastric Cancer | Phase 1 / Phase 2 | Completed | MedPacto, Inc. | 120 | 2018-12-20 | 2025-03-25 |
| TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer TEW-7197 - Metastatic Gastric Cancer | Phase 1 / Phase 2 | Completed | MedPacto, Inc. | 62 | 2018-08-15 | 2024-12-09 |
| Effect of Food on the Pharmacokinetics of TEW-7197 in Healthy Subjects TEW-7197 - Healthy Volunteers | Phase 1 | Completed | MedPacto, Inc. | 16 | 2018-08-08 | 2020-04-14 |
| Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS TEW-7197 - Myelodysplastic Syndromes | Phase 1 | Completed | MedPacto, Inc. | 9 | 2018-01-04 | 2021-09-28 |
| First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors TEW-7197 - Advanced Stage Solid Tumors | Phase 1 | Completed | MedPacto, Inc. | 35 | 2014-07-29 | 2019-05-09 |
Colorectal Neoplasms (2) · Osteosarcoma (2) · Stomach Neoplasms (2) · Camurati-Engelmann Syndrome (1) · Carcinoma, Non-Small-Cell Lung (1) · Dermoid Cyst (1) · Keratoacanthoma familial (1) · Myelodysplastic Syndromes (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Pathologic Complete Response (1)
vactosertib (8) · pembrolizumab (2) · BID protein, human (1) · Hepatectomy (1) · Imatinib Mesylate (1) · durvalumab (1)
South Korea (8) · United States (5)
Sunjin Hwang, MD (4) · Minkyu Heo (3) · Chloe Atreya, MD, Ph.D. (1) · Ilho Ha, PhD (1) · Lawrence Fong, MD (1)